TScan Therapeutics

TScan Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TScan Therapeutics (TCRX) as of Oct 19, 2026 is -135.81 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -134.82 M USD — a change of 0.74% (lower).

EBITDA

-135.81 MUSD

YoY

0.74%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TScan Therapeutics is 2025 -135.81 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TScan Therapeutics was 2024 -134.82 M USD. It decreases by 0.74% lower compared to the previous year.

The TScan Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-14.21 M USD
Jan 1, 2020
-26.23 M USD
Jan 1, 2021
-48.64 M USD
Jan 1, 2022
-66.64 M USD
Jan 1, 2023
-93.46 M USD
Jan 1, 2024
-134.82 M USD
Jan 1, 2025
-135.81 M USD
The TScan Therapeutics EBITDA history
YEAREBITDAYoY
-135.81 MUSD+0.74%
-134.82 MUSD+44.26%
-93.46 MUSD+40.25%
-66.64 MUSD+37.00%
-48.64 MUSD+85.42%
-26.23 MUSD+84.61%
-14.21 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TScan Therapeutics Stock analysis

What does TScan Therapeutics do? TScan Therapeutics Inc., based in Waltham, Massachusetts, is a biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. The company, which went public on July 16, 2021, employs 145 people and is advancing a pipeline of therapies targeting liquid cancers, solid tumors, and other serious diseases. Its lead candidates, TSC-100 and TSC-101, are in clinical development for hematologic malignancies, while it also develops multiplexed TCR-T therapies and maintains an ImmunoBank of solid tumor targets across various HLA types. TScan Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TScan Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TScan Therapeutics is -135.81 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TScan Therapeutics changed from -134.82 M USD to -135.81 M USD, representing a 0.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) TScan Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TScan Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — TScan Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — TScan Therapeutics